The Women’s Tennis Association (WTA) will require all players to undergo a one-time screening for the SRY gene starting in 2026 to confirm eligibility for the women’s tour. This policy change, announced by the WTA, shifts away from previous rules that allowed transgender women to compete based on self-identified gender and testosterone suppression, aligning the organization with broader trends in international sports governance.
Shifting Eligibility Standards in Professional Sports
The implementation of SRY gene testing marks a definitive move toward biological sex-based categorization in professional tennis. According to the WTA, players can fulfill the requirement via a simple cheek swab or blood test.
This policy replaces the former standard, which permitted transgender women to participate if they declared their gender as female and maintained testosterone levels below a specific threshold for two years. While these older regulations were in place, the WTA reports that there are no known transgender women currently active at any level of professional tennis.
Did you know?
Industry-Wide Alignment with Olympic Protocols
The WTA’s decision mirrors recent updates from other major athletic governing bodies. In March, the International Olympic Committee (IOC) established that only biological female athletes, as determined by a one-time test, are eligible for female category events at the Olympic Games. Similar gene-based screening protocols have also been adopted by World Athletics and World Boxing.
These movements reflect a growing consensus among various federations to prioritize biological sex markers over hormonal regulation as the primary criterion for female-category eligibility. Critics of previous inclusion policies, such as 18-time Grand Slam champion Martina Navratilova, have long argued that the physical advantages gained during male puberty are not sufficiently mitigated by hormone therapy. Conversely, advocates such as Billie Jean King have characterized the exclusion of transgender athletes as a form of discrimination.
The Evolution of Eligibility Policy
The history of transgender participation in professional tennis has been a subject of debate for decades. Renee Richards, a transgender athlete, famously competed on the women’s professional tour between 1977 and 1981. Since that era, the conversation regarding competitive fairness has become a centerpiece of sports policy.
The WTA has stated that it recognizes the complexity of this issue. A spokesperson for the association noted that the transition to the new screening process will be handled with confidentiality and data privacy safeguards. The organization also plans to launch a comprehensive player engagement program to support athletes as the policy takes effect.
Pro Tip:
When tracking changes in sports eligibility, monitor the official policy documents of international federations like the IOC or World Athletics, as these often serve as the blueprint for regional and professional associations.
Frequently Asked Questions
Why is the WTA implementing SRY gene testing?
The WTA is updating its policy to confirm eligibility for the women’s tour through a standardized, one-time screening process for the SRY gene, which is a biological marker for male sex development.
When does the new WTA policy take effect?
The new eligibility policy, including the required SRY gene test, comes into effect on Tuesday, with player screenings scheduled to begin in 2026.
How is the test conducted?
Are there currently transgender women playing on the WTA tour?
No. The WTA has stated that there are no known transgender women currently active at any level of professional tennis.
What are your thoughts on the evolving standards for professional sports eligibility? Share your perspective in the comments below or subscribe to our newsletter for ongoing updates on sports regulation and policy.
Worth a look